Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment
- 31 May 2009
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 113 (2), 216-220
- https://doi.org/10.1016/j.ygyno.2008.12.026
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2008
- Serum protein markers for early detection of ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2005
- Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupportive Care in Cancer, 2004
- A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physiciansGynecologic Oncology, 2004
- Treatment Preferences in Recurrent Ovarian CancerGynecologic Oncology, 2002
- The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.1999
- A review of the use of health status measures in economic evaluation.Health Technology Assessment, 1999
- Perceptions of Cisplatin-Related Toxicity among Ovarian Cancer Patients and Gynecologic OncologistsGynecologic Oncology, 1998
- Palliative therapy in advanced ovarian cancerAnti-Cancer Drugs, 1998
- Cost–Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian CancerGynecologic Oncology, 1997